# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0148 |
| Population Package | PP-0148 |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| No overlap with adjacent Population Packages | PASS |
| Atomic Knowledge Principle preserved | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ACMG/AMP | PASS |
| Consistent with ClinGen SVI principles | PASS |
| Appropriate explanation of BS4 | PASS |
| Affected-member requirement correctly represented | PASS |
| Phenotype-positive/genotype-negative distinction preserved | PASS |
| Inheritance pattern appropriately addressed | PASS |
| Penetrance appropriately addressed | PASS |
| Phenocopy caveat appropriately addressed | PASS |
| Multiple-pathogenic-variant caveat appropriately addressed | PASS |
| Disease-specific VCEP implementation acknowledged | PASS |
| Gastric-cancer context preserved | PASS |
| CDH1-specific BS4 non-applicability correctly encoded | PASS |
| No unsupported clinical claim | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for gastric-cancer patients and caregivers | PASS |
| Learning objectives satisfied | PASS |
| Co-segregation explained | PASS |
| Non-segregation explained | PASS |
| Affected family member explained | PASS |
| Phenocopy concept explained | PASS |
| Alternative molecular cause explained | PASS |
| "Affected relative without variant = benign" misconception corrected | PASS |
| PP1 versus BS4 distinction explained | PASS |
| Technical implementation appropriately deferred | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Gastric-cancer context preserved | PASS |
| Disease-specific governance boundary encoded | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No unsafe medical advice | PASS |
| No automatic benign classification implied | PASS |
| No "one affected relative = BS4" shortcut | PASS |
| Phenocopy risk emphasized | PASS |
| Alternative pathogenic variants emphasized | PASS |
| Penetrance emphasized | PASS |
| Age emphasized | PASS |
| Disease-specific guidance emphasized | PASS |
| Gastric-cancer context preserved | PASS |
| CDH1-specific limitation preserved | PASS |
| No treatment recommendations | PASS |

---

# Educational Boundary Review

The Population Package remains within the predefined educational boundary.

### Included

- BS4 definition
- Co-segregation/non-segregation
- Affected family members
- Genotype-positive/genotype-negative distinction
- Inheritance
- Penetrance
- Phenocopies
- Alternative pathogenic variants
- Disease-specific interpretation
- Gastric-cancer context

### Excluded

- Quantitative segregation statistics
- Bayesian likelihood ratios
- BayesScore
- PP1 technical implementation
- Minimum meiosis/family thresholds
- Detailed pedigree modelling
- Penetrance calculations
- Disease-specific formulas
- Treatment recommendations

The **Atomic Knowledge Principle** has been fully preserved.

---

# Runtime Safety Review

The Safe Medical AI System must avoid statements such as:

- "An affected relative without the variant proves the variant is benign."
- "Any family member with gastric cancer can be counted as affected."
- "BS4 applies to every hereditary gastric-cancer gene."
- "One non-segregating relative is always Strong Benign Evidence."

Instead, the system should communicate that BS4 requires interpretation of:

- the specific disease phenotype;
- reliable genotype information;
- inheritance model;
- penetrance;
- age;
- possible phenocopies;
- alternative molecular explanations;
- and applicable disease-specific ClinGen guidance.

For **CDH1**, the current ClinGen Expert Panel specification states that BS4 is **not applicable**. This is a critical gastric-cancer-specific governance safeguard. ([clinicalgenome.org](https://clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf))

---

# Final Quality Decision

## PASS

PP-0148 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0148 — BS4 (Lack of Co-segregation in Affected Members of a Family)**

---

# Reviewer Notes

The most important safety feature of this package is preservation of the distinction between:

**non-segregation**

and

**proof of benignity**.

This is particularly important in gastric cancer because phenocopies can occur and different genetic causes may produce overlapping cancer phenotypes.

The current ClinGen CDH1 Expert Panel specification provides a concrete gastric-cancer example in which the generic BS4 criterion is explicitly **not applicable**. ([clinicalgenome.org](https://clinicalgenome.org/site/assets/files/7580/clingen_cdh1_acmg_specifications_v3_1.pdf))

The package therefore deliberately teaches the generic ACMG/AMP principle while requiring disease/gene-specific governance before runtime application.

The package maintains strict adherence to the **Atomic Knowledge Principle** and the locked **Gold Workflow**.